This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy and Safety Trial to Assess Moxifloxacin in Treating Community-Acquired Pneumonia (CAP) With Aspiration Factors

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified March 2009 by Beijing Hospital.
Recruitment status was:  Recruiting
Information provided by:
Beijing Hospital Identifier:
First received: September 15, 2008
Last updated: March 10, 2009
Last verified: March 2009
The purpose of this study is to determine whether moxifloxacin in comparison to levofloxacin plus metronidazole are effective and safe in the treatment of community-acquired pneumonia with aspiration factors.

Condition Intervention Phase
Community-Acquired Pneumonia Drug: moxifloxacin Drug: levofloxacin Drug: metronidazole Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Multi-Centre, Prospective, Open Label, Randomized Trial to Assess the Efficacy and Safety of Moxifloxacin Versus Levofloxacin Plus Metronidazole in the Treatment of Community-Acquired Pneumonia With Aspiration Factors

Resource links provided by NLM:

Further study details as provided by Beijing Hospital:

Primary Outcome Measures:
  • Clinical response [ Time Frame: Test-of-cure visit (7-14 days after the end of treatment) ]

Estimated Enrollment: 186
Study Start Date: September 2008
Estimated Study Completion Date: May 2010
Estimated Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: moxifloxacin
Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
Other Name: Avelox
Active Comparator: B Drug: levofloxacin
Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
Drug: metronidazole
metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks

Detailed Description:

186 patients in 4 centers will be enrolled in this study. Patients accord with the criteria of CAP with aspiration factors will be enrolled and randomized to one of the following groups. The treatment duration will range from 2 to 4 weeks.

Study Group: Intravenous treatment with moxifloxacin 400mg i.v. OD. Based on investigator's decision, a switch can be made to moxifloxacin 400 mg OD, orally (Moxifloxacin injection will be used no more than 3 weeks consecutively) .

Control Group: Intravenous treatment with levofloxacin 400mg i.v. OD plus metronidazole 0.5g i.v. bid. Based on investigator's decision, a switch can be made to levofloxacin 400mg OD plus metronidazole 0.2g tid, orally.

Treatment should be continued until complete resolution of the radiological, clinical and laboratory alterations or until no further regression can be observed. Clinical, bacteriological, laboratory and radiological examinations will be performed pre-treatment. Swallowing/coughing reflection test will be used for aspiration factor diagnosis. Risk factors (Decreased level of consciousness, dysphagia, gastroesophageal reflux, neurologic disease, mechanical and device-related (e.g. nasogastric feeding tube) impairment of upper aerodigestive tract, vomiting, bronchial obstruction due to neoplasm or foreign body, bronchiectasis, pulmonary infarction, etc) will be evaluated before the treatment. Clinical and laboratory examinations such as blood routine(including Hb, differential blood count, etc), urine routine, biochemistry examination (including serum bilirubin, hepatic/renal function parameters, etc), coagulation examination will be repeated selectively. Radiological examination (e.g. chest x-ray) will be repeated at each visit for clinical monitoring after one week treatment. At the test-of-cure visit (7-14 days after the end of therapy) comprehensive clinical, bacteriological and laboratory examinations will be performed.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female patients aged 18 years or above.
  • Patients who are willing and able to provide written informed consent.
  • Accord with the diagnosis criteria of CAP based on clinical, radiological and microbiological findings.
  • With aspiration factors (Including swallowing or coughing reflection test positive)

Exclusion Criteria:

  • Known hypersensitivity to fluoroquinolones and/or metronidazole.
  • Female patients who are pregnant or lactating.
  • Patients with mechanical ventilation lasting more than 48 hours prior to enrollment.
  • Patients with neutropenia (neutrophil count <1.000/mm3) due to malignancy or chemotherapy.
  • Patients with a severe, life-threatening disease with a life expectancy of less than 2 months.
  • Patients with a co-existent disease considered likely to affect the outcome of the study (e.g. lung cancer, cystic fibrosis, collagen vascular disease affecting the lungs, pleural empyema, severe cardiac failure class III or IV of the NYHA).
  • Patients with poststenotic pneumonia (e.g. in connection with carcinoma of the lung).
  • Patients with acute infarction pneumonia.
  • Patients with active pulmonary tuberculosis.
  • Patients with lung abscess/pneumonia with concomitant endocarditis.
  • Patients with known i.v. drug abuse.
  • Patients known to have AIDS (CD4 count <200/ul) or HIV-seropositives who are receiving HAART (highly activated antiretroviral therapy). Note: HIV-positive patients may be included. HIV testing is not required for this study protocol.
  • Patients with severe hepatic impairment (Child-Pugh C).
  • Patients on hemodialysis, equivalent to creatinine clearance <15 ml/min/1.73 m2.
  • Patients known to have congenital or sporadic syndromes of QTc prolongation, or are receiving concomitant medication reported to increase the QTc interval, e.g. amiodaron, sotalol, disopyramide, quinidine, procainamide, terfenadine.
  • Previous history of tendinopathy with quinolones.
  • Patients who have previously been included in this study.
  • Patients with any investigational drug within 30 days of screening.
  • Patients requiring concomitant systemic antibacterial agents.
  • Pre-treatment with a systemic antibacterial agent within 24 hours prior to enrollment (Except for the cases that pre-treatment is not effective based on the clinical judgment).
  • Severe CAP.
  • Other contraindications in package insert.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00752947

Contact: Tieying Sun 86-10-13701034257

Tieying Sun Recruiting
Beijing, China
Xiuhong Nie Not yet recruiting
Beijing, China
Sponsors and Collaborators
Beijing Hospital
Principal Investigator: Tieying Sun Beijing Hospital
  More Information

Responsible Party: Prof. Sun Tieying, Beijing Hospital Identifier: NCT00752947     History of Changes
Other Study ID Numbers: MOHBJH-STY-1
Study First Received: September 15, 2008
Last Updated: March 10, 2009

Additional relevant MeSH terms:
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents, Urinary
Renal Agents
Anti-Bacterial Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Nucleic Acid Synthesis Inhibitors processed this record on June 23, 2017